Immunovant Awarded U.S. Patent for IMVT-1402
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Goldman Sachs Starts Immunovant (IMVT) at Buy
March 13, 2024 5:29 AM EDTGoldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ: IMVT) with a Buy rating and a price target of $50.00.
The analyst comments "We initiate coverage of IMVT with a Buy rating and 12-month price target of $50 (60% upside potential). We see potential for IMVT-1402... More
